President and CEO of Supernus. “In addition, we are pleased to be bringing ONAPGO to market, another growth driver for our business. ONAPGO represents a novel approach for adults with Parkinson’s ...

President and CEO of Supernus. "In addition, we are pleased to be bringing ONAPGO to market, another growth driver for our business. ONAPGO represents a novel approach for adults with Parkinson's ...

ONAPGO (apomorphine hydrochloride) launched in the U.S. in April 2025. The Company reiterates full year 2025 financial guidance. ROCKVILLE, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Supernus ...

The company launched ONAPGO™, a new treatment for Parkinson's disease, in April 2025 and saw significant growth in Qelbree prescriptions, which rose by 22%. Supernus reiterated its full year ...

President and CEO of Supernus. “In addition, we are pleased to be bringing ONAPGO to market, another growth driver for our business. ONAPGO represents a novel approach for adults with Parkinson ...

ONAPGO™ (apomorphine hydrochloride) launched in the U.S. in April 2025. The Company reiterates full year 2025 financial guidance. ROCKVILLE, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Supernus ...

ONAPGO™ (apomorphine hydrochloride) launched in the U.S. in April 2025. The Company reiterates full year 2025 financial guidance. ROCKVILLE, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Supernus ...

ROCKVILLE, Md. (AP) — ROCKVILLE, Md. (AP) — Supernus Pharmaceuticals Inc. (SUPN) on Tuesday reported a loss of $11.8 million in its first quarter. The Rockville, Maryland-based company said it ...

Investing.com -- Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) climbed 5.5% Tuesday as the U.S. Food and Drug Administration approved ONAPGO for the treatment of motor fluctuations in adults with ...